Key result
PARP inhibition with PJ34 reversed the attenuation of endothelium-dependent responses and biochemical changes induced by plasma from women with pre-eclampsia.
Why the study?
Does PARP inhibition with PJ34 improve endothelium-dependent responses and reduce oxidative stress in models of pre-eclampsia?
Does PARP inhibition with PJ34 improve endothelium-dependent responses and reduce oxidative stress in models of pre-eclampsia?
PARP inhibition reverses endothelial dysfunction induced by pre-eclamptic plasma in vitro, suggesting a potential therapeutic target for pre-eclampsia.
Answers are grounded in this paper and cite their sources.
PARP activation may drive endothelial dysfunction in pre-eclampsia; hypothesis-generating, prospective confirmation required before clinical consideration.
Pre-eclampsia is a serious pregnancy disorder associated with widespread activation of the maternal vascular endothelium. Recent evidence implicates a role for oxidative stress in the aetiology of this condition. 2. Reactive oxygen species, particularly superoxide anions, invokes endothelial cell activation through many pathways. Oxidant-induced cell injury triggers the activation of nuclear enzyme poly(ADP-ribose) polymerase (PARP) leading to endothelial dysfunction in various pathophysiological conditions (reperfusion, shock, diabetes). 3. We have studied whether the loss of endothelial function in pre-eclampsia is dependent on PARP activity. Endothelium-dependent responses of myometrial arteries were tested following exposure to either plasma from women with pre-eclampsia or normal pregnant women in the presence and absence of a novel potent inhibitor of PARP, PJ34. Additional effects of plasma and PJ34 inhibition were identified in microvascular endothelial cell cultures. 4. In myometrial arteries, PARP inhibition blocked the attenuation of endothelium-dependent responses following exposure to plasma from women with pre-eclampsia. In endothelial cell cultures, plasma from pre-eclamptics induced measurable oxidative stress and a concomitant increase in PARP activity and reduction in cellular ATP. Again, these biochemical changes were reversed by PJ34. 5. These results suggest that PARP activity plays a pathogenic role in the development of endothelial dysfunction in pre-eclampsia and promotes PARP inhibition as a potential therapy in this condition.
No takes yet. Share an insight, caveat, or question.
Crocker et al. (2005) studied Pre-eclampsia. PJ34 (PARP inhibitor) vs. Absence of PJ34 was evaluated on Endothelium-dependent responses and biochemical changes (oxidative stress, PARP activity, cellular ATP). PARP inhibition with PJ34 reversed the attenuation of endothelium-dependent responses and biochemical changes induced by plasma from women with pre-eclampsia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: